Will UnitedHealth Stock Recover?
Shares of embattled health insurance giant UnitedHealth (NYSE:UNH) plummeted by…
Sell
50
PRAX Quote, Financials, Valuation and Earnings
Last price:
$333.20
Seasonality move
:
-38.16%
Day range:
$302.00 - $324.79
52-week range:
$26.70 - $328.60
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
914.99x
P/B ratio:
23.54x
Volume:
463.4K
Avg. volume:
568.4K
1-year change:
283.77%
Market cap:
$8.1B
Revenue:
$8.6M
EPS (TTM):
-$12.90
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
PRAX
Praxis Precision Medicines, Inc.
|
$256.1K | -$3.13 | -96.57% | -7.79% | $570.38 |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$230.8M | -$0.37 | -87.58% | -73.49% | $81.67 |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$835.5M | $0.67 | 11.91% | 37.43% | $89.09 |
|
FOLD
Amicus Therapeutics, Inc.
|
$185M | $0.18 | 29.62% | 267.32% | $14.50 |
|
MRKR
Marker Therapeutics, Inc.
|
$682K | -$0.19 | -69.71% | -54.94% | $7.87 |
|
VRDN
Viridian Therapeutics, Inc.
|
$15.8M | -$1.00 | -82.64% | -1.73% | $42.06 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
PRAX
Praxis Precision Medicines, Inc.
|
$323.29 | $570.38 | $8.1B | -- | $0.00 | 0% | 914.99x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$61.55 | $81.67 | $8.6B | 40.01x | $0.00 | 0% | 7.76x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$60.31 | $89.09 | $11.6B | 22.60x | $0.00 | 0% | 3.82x |
|
FOLD
Amicus Therapeutics, Inc.
|
$14.31 | $14.50 | $4.4B | -- | $0.00 | 0% | 7.32x |
|
MRKR
Marker Therapeutics, Inc.
|
$1.46 | $7.87 | $24.3M | -- | $0.00 | 0% | 3.96x |
|
VRDN
Viridian Therapeutics, Inc.
|
$30.07 | $42.06 | $2.9B | -- | $0.00 | 0% | 34.49x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
PRAX
Praxis Precision Medicines, Inc.
|
0.13% | 4.284 | 0.04% | 5.05x |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
54.75% | 3.853 | 7.54% | 3.27x |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
9.17% | -0.896 | 5.87% | 2.84x |
|
FOLD
Amicus Therapeutics, Inc.
|
65.77% | -0.293 | 18.22% | 1.91x |
|
MRKR
Marker Therapeutics, Inc.
|
-- | 2.330 | -- | 5.66x |
|
VRDN
Viridian Therapeutics, Inc.
|
4.52% | 1.855 | 1.21% | 11.06x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
PRAX
Praxis Precision Medicines, Inc.
|
-$19K | -$78.4M | -67.57% | -67.75% | -856.97% | -$64.7M |
|
ARWR
Arrowhead Pharmaceuticals, Inc.
|
$257.6M | $40.8M | 19.23% | 50.21% | 15.46% | $11.3M |
|
BMRN
BioMarin Pharmaceutical, Inc.
|
$641.8M | $184.9M | 8.12% | 8.99% | 23.5% | $334.9M |
|
FOLD
Amicus Therapeutics, Inc.
|
$147.7M | $34.3M | -2.18% | -7.02% | 20.27% | $35.3M |
|
MRKR
Marker Therapeutics, Inc.
|
-- | -$2.1M | -103.04% | -103.04% | -173.31% | -$2.7M |
|
VRDN
Viridian Therapeutics, Inc.
|
$70.3M | -$40M | -46.01% | -47.79% | -56.7% | -$84.7M |
Praxis Precision Medicines, Inc. vs. Competitors
-
Which has Higher Returns PRAX or ARWR?
Arrowhead Pharmaceuticals, Inc. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of 10.7%. Praxis Precision Medicines, Inc.'s return on equity of -67.75% beat Arrowhead Pharmaceuticals, Inc.'s return on equity of 50.21%.
Company Gross Margin Earnings Per Share Invested Capital PRAXPraxis Precision Medicines, Inc.-- -$3.36 $343.9M ARWRArrowhead Pharmaceuticals, Inc.97.58% $0.22 $1.3B -
What do Analysts Say About PRAX or ARWR?
Praxis Precision Medicines, Inc. has a consensus price target of $570.38, signalling upside risk potential of 76.43%. On the other hand Arrowhead Pharmaceuticals, Inc. has an analysts' consensus of $81.67 which suggests that it could grow by 32.68%. Given that Praxis Precision Medicines, Inc. has higher upside potential than Arrowhead Pharmaceuticals, Inc., analysts believe Praxis Precision Medicines, Inc. is more attractive than Arrowhead Pharmaceuticals, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRAXPraxis Precision Medicines, Inc.12 1 1 ARWRArrowhead Pharmaceuticals, Inc.7 4 0 -
Is PRAX or ARWR More Risky?
Praxis Precision Medicines, Inc. has a beta of 2.836, which suggesting that the stock is 183.641% more volatile than S&P 500. In comparison Arrowhead Pharmaceuticals, Inc. has a beta of 1.213, suggesting its more volatile than the S&P 500 by 21.339%.
-
Which is a Better Dividend Stock PRAX or ARWR?
Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Arrowhead Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. Arrowhead Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRAX or ARWR?
Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than Arrowhead Pharmaceuticals, Inc. quarterly revenues of $264M. Praxis Precision Medicines, Inc.'s net income of -$73.9M is lower than Arrowhead Pharmaceuticals, Inc.'s net income of $28.2M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while Arrowhead Pharmaceuticals, Inc.'s PE ratio is 40.01x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 914.99x versus 7.76x for Arrowhead Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRAXPraxis Precision Medicines, Inc.914.99x -- -- -$73.9M ARWRArrowhead Pharmaceuticals, Inc.7.76x 40.01x $264M $28.2M
-
Which has Higher Returns PRAX or BMRN?
BioMarin Pharmaceutical, Inc. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of -3.91%. Praxis Precision Medicines, Inc.'s return on equity of -67.75% beat BioMarin Pharmaceutical, Inc.'s return on equity of 8.99%.
Company Gross Margin Earnings Per Share Invested Capital PRAXPraxis Precision Medicines, Inc.-- -$3.36 $343.9M BMRNBioMarin Pharmaceutical, Inc.81.58% -$0.16 $6.7B -
What do Analysts Say About PRAX or BMRN?
Praxis Precision Medicines, Inc. has a consensus price target of $570.38, signalling upside risk potential of 76.43%. On the other hand BioMarin Pharmaceutical, Inc. has an analysts' consensus of $89.09 which suggests that it could grow by 47.72%. Given that Praxis Precision Medicines, Inc. has higher upside potential than BioMarin Pharmaceutical, Inc., analysts believe Praxis Precision Medicines, Inc. is more attractive than BioMarin Pharmaceutical, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRAXPraxis Precision Medicines, Inc.12 1 1 BMRNBioMarin Pharmaceutical, Inc.14 6 0 -
Is PRAX or BMRN More Risky?
Praxis Precision Medicines, Inc. has a beta of 2.836, which suggesting that the stock is 183.641% more volatile than S&P 500. In comparison BioMarin Pharmaceutical, Inc. has a beta of 0.256, suggesting its less volatile than the S&P 500 by 74.362%.
-
Which is a Better Dividend Stock PRAX or BMRN?
Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioMarin Pharmaceutical, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. BioMarin Pharmaceutical, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRAX or BMRN?
Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than BioMarin Pharmaceutical, Inc. quarterly revenues of $786.8M. Praxis Precision Medicines, Inc.'s net income of -$73.9M is lower than BioMarin Pharmaceutical, Inc.'s net income of -$30.7M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while BioMarin Pharmaceutical, Inc.'s PE ratio is 22.60x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 914.99x versus 3.82x for BioMarin Pharmaceutical, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRAXPraxis Precision Medicines, Inc.914.99x -- -- -$73.9M BMRNBioMarin Pharmaceutical, Inc.3.82x 22.60x $786.8M -$30.7M
-
Which has Higher Returns PRAX or FOLD?
Amicus Therapeutics, Inc. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of 10.24%. Praxis Precision Medicines, Inc.'s return on equity of -67.75% beat Amicus Therapeutics, Inc.'s return on equity of -7.02%.
Company Gross Margin Earnings Per Share Invested Capital PRAXPraxis Precision Medicines, Inc.-- -$3.36 $343.9M FOLDAmicus Therapeutics, Inc.87.38% $0.06 $673.2M -
What do Analysts Say About PRAX or FOLD?
Praxis Precision Medicines, Inc. has a consensus price target of $570.38, signalling upside risk potential of 76.43%. On the other hand Amicus Therapeutics, Inc. has an analysts' consensus of $14.50 which suggests that it could grow by 1.33%. Given that Praxis Precision Medicines, Inc. has higher upside potential than Amicus Therapeutics, Inc., analysts believe Praxis Precision Medicines, Inc. is more attractive than Amicus Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRAXPraxis Precision Medicines, Inc.12 1 1 FOLDAmicus Therapeutics, Inc.0 7 0 -
Is PRAX or FOLD More Risky?
Praxis Precision Medicines, Inc. has a beta of 2.836, which suggesting that the stock is 183.641% more volatile than S&P 500. In comparison Amicus Therapeutics, Inc. has a beta of 0.381, suggesting its less volatile than the S&P 500 by 61.857%.
-
Which is a Better Dividend Stock PRAX or FOLD?
Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amicus Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. Amicus Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRAX or FOLD?
Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than Amicus Therapeutics, Inc. quarterly revenues of $169.1M. Praxis Precision Medicines, Inc.'s net income of -$73.9M is lower than Amicus Therapeutics, Inc.'s net income of $17.3M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while Amicus Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 914.99x versus 7.32x for Amicus Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRAXPraxis Precision Medicines, Inc.914.99x -- -- -$73.9M FOLDAmicus Therapeutics, Inc.7.32x -- $169.1M $17.3M
-
Which has Higher Returns PRAX or MRKR?
Marker Therapeutics, Inc. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of -162.11%. Praxis Precision Medicines, Inc.'s return on equity of -67.75% beat Marker Therapeutics, Inc.'s return on equity of -103.04%.
Company Gross Margin Earnings Per Share Invested Capital PRAXPraxis Precision Medicines, Inc.-- -$3.36 $343.9M MRKRMarker Therapeutics, Inc.-- -$0.12 $18.4M -
What do Analysts Say About PRAX or MRKR?
Praxis Precision Medicines, Inc. has a consensus price target of $570.38, signalling upside risk potential of 76.43%. On the other hand Marker Therapeutics, Inc. has an analysts' consensus of $7.87 which suggests that it could grow by 438.81%. Given that Marker Therapeutics, Inc. has higher upside potential than Praxis Precision Medicines, Inc., analysts believe Marker Therapeutics, Inc. is more attractive than Praxis Precision Medicines, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRAXPraxis Precision Medicines, Inc.12 1 1 MRKRMarker Therapeutics, Inc.3 0 0 -
Is PRAX or MRKR More Risky?
Praxis Precision Medicines, Inc. has a beta of 2.836, which suggesting that the stock is 183.641% more volatile than S&P 500. In comparison Marker Therapeutics, Inc. has a beta of 1.442, suggesting its more volatile than the S&P 500 by 44.218%.
-
Which is a Better Dividend Stock PRAX or MRKR?
Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Marker Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. Marker Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRAX or MRKR?
Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than Marker Therapeutics, Inc. quarterly revenues of $1.2M. Praxis Precision Medicines, Inc.'s net income of -$73.9M is lower than Marker Therapeutics, Inc.'s net income of -$2M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while Marker Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 914.99x versus 3.96x for Marker Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRAXPraxis Precision Medicines, Inc.914.99x -- -- -$73.9M MRKRMarker Therapeutics, Inc.3.96x -- $1.2M -$2M
-
Which has Higher Returns PRAX or VRDN?
Viridian Therapeutics, Inc. has a net margin of -786.27% compared to Praxis Precision Medicines, Inc.'s net margin of -49.03%. Praxis Precision Medicines, Inc.'s return on equity of -67.75% beat Viridian Therapeutics, Inc.'s return on equity of -47.79%.
Company Gross Margin Earnings Per Share Invested Capital PRAXPraxis Precision Medicines, Inc.-- -$3.36 $343.9M VRDNViridian Therapeutics, Inc.99.56% -$0.42 $526.8M -
What do Analysts Say About PRAX or VRDN?
Praxis Precision Medicines, Inc. has a consensus price target of $570.38, signalling upside risk potential of 76.43%. On the other hand Viridian Therapeutics, Inc. has an analysts' consensus of $42.06 which suggests that it could grow by 39.87%. Given that Praxis Precision Medicines, Inc. has higher upside potential than Viridian Therapeutics, Inc., analysts believe Praxis Precision Medicines, Inc. is more attractive than Viridian Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings PRAXPraxis Precision Medicines, Inc.12 1 1 VRDNViridian Therapeutics, Inc.14 1 0 -
Is PRAX or VRDN More Risky?
Praxis Precision Medicines, Inc. has a beta of 2.836, which suggesting that the stock is 183.641% more volatile than S&P 500. In comparison Viridian Therapeutics, Inc. has a beta of 0.962, suggesting its less volatile than the S&P 500 by 3.833%.
-
Which is a Better Dividend Stock PRAX or VRDN?
Praxis Precision Medicines, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Viridian Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines, Inc. pays -- of its earnings as a dividend. Viridian Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios PRAX or VRDN?
Praxis Precision Medicines, Inc. quarterly revenues are --, which are smaller than Viridian Therapeutics, Inc. quarterly revenues of $70.6M. Praxis Precision Medicines, Inc.'s net income of -$73.9M is lower than Viridian Therapeutics, Inc.'s net income of -$34.6M. Notably, Praxis Precision Medicines, Inc.'s price-to-earnings ratio is -- while Viridian Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines, Inc. is 914.99x versus 34.49x for Viridian Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income PRAXPraxis Precision Medicines, Inc.914.99x -- -- -$73.9M VRDNViridian Therapeutics, Inc.34.49x -- $70.6M -$34.6M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Lumentum The Best Laser Stock to Buy?
Though certainly less well-known than the huge tech businesses that…
Is Planet Fitness Stock Undervalued?
Planet Fitness (NYSE:PLNT) has had a difficult 12 months, retreating…
Stock Ideas
Buy
56
Is NVDA Stock a Buy?
Market Cap: $4.6T
P/E Ratio: 65x
Buy
58
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 37x
Sell
40
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 29x
Alerts
Buy
91
TDC alert for Feb 12
Teradata Corp. [TDC] is down 11.64% over the past day.
Buy
67
DIOD alert for Feb 12
Diodes, Inc. [DIOD] is down 7.63% over the past day.
Buy
77
VRT alert for Feb 12
Vertiv Holdings Co. [VRT] is down 4.79% over the past day.
